Celebrex (Celecoxib) Treatment of Laryngeal Papilloma

Summary

Respiratory recurrent papilloma (RRP) is one of the most common benign tumors. Surgical removal is the current management for RRP, but it is a very traumatic procedure, and often leads to permanent voice dysfunction. In this study, we will develop a new, combined RRP treatment with a pulsed dye laser (PDL) and Celebrex. We will determine if Celebrex, a newly developed inhibitor of cyclooxygenase (COX)-2, can provide a long-term inhibitory effect on RRP, therefore preventing RRP from recurring. This combined strategy, if successful in this proposed study, will provide a new and ideal "voice-preserving" therapy for RRP that will deliver long-term efficacy in managing RRP.

Timeline

Start

2005-05

Primary completion

2009-07

Completion

2009-07

Outcome

Outcome not reported

Stopped (Business): “03/01/2009,due to date close to termination of this funding/study period”

Drugs

Indications